PULSTEC INDUSTRIAL (6894) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Operating income increased substantially faster than revenue, making margin improvement the most important feature of the current-period results. Revenue remained limited to ¥16.3B (+1.7% YoY), while operating income rose to ¥2.0B (+33.0%), ordinary income to ¥2.3B (+29.9%), and net income to ¥1.6B (+45.3%), securing profit growth well above the revenue growth rate. Growth in the core X-ray residual stress measurement equipment business and company-wide cost absorption drove the increase in profit; however, progress toward the full-year forecast remains below the standard 75% level for both revenue and profit, making Q4 performance crucial to achieving the plan.

Factors Affecting Business Performance

【Revenue】Revenue of ¥16.3B increased only slightly, by +1.7% YoY. By segment, the X-ray residual stress measurement equipment business grew significantly to ¥6.65B (+45.8% YoY), driving company-wide growth, while the healthcare equipment business declined substantially to ¥3.25B (-37.2% YoY), acting as an offsetting factor. The optical application and special equipment business was essentially flat at ¥6.42B (+1.6% YoY).

【Profit and Loss】Operating income of ¥2.0B (+33.0% YoY) and the operating margin of 12.3% both expanded from the same period of the previous year. By segment, the X-ray residual stress measurement equipment business recorded substantial profit growth to ¥2.64B (+66.4% YoY), while the healthcare equipment business swung to a loss of ¥0.07B and the optical application and special equipment business recorded lower profit of ¥1.74B (-9.5% YoY). In extraordinary gains and losses, a loss on disposal of fixed assets of ¥0.14B was recorded in the same period of the previous year but did not occur in the current period, representing a temporary factor. The divergence between ordinary income and net income was primarily attributable to the tax burden (effective tax rate of 30.4%), with no significant distortion from non-operating or extraordinary factors. The company achieved both revenue and profit growth, with the profit growth rate substantially exceeding the revenue growth rate.

Segment Analysis

The X-ray residual stress measurement equipment business was the largest growth and profit driver, with revenue of ¥6.65B (+45.8% YoY) and segment profit of ¥2.64B (+66.4% YoY). The optical application and special equipment business was essentially flat in terms of revenue at ¥6.42B (+1.6% YoY), while segment profit declined to ¥1.74B (-9.5% YoY). The healthcare equipment business recorded a substantial revenue decline to ¥3.25B (-37.2% YoY), with segment profit turning to a loss of ¥0.07B from a profit of ¥0.32B in the same period of the previous year. Of total segment profit of ¥4.30B, the X-ray residual stress measurement equipment business accounted for approximately 61%, indicating a high degree of reliance on this segment for profit generation.

Key Financial Indicators

【Profitability】The operating margin of 12.3% and net profit margin of 9.7% both improved from the same period of the previous year, reflecting the absorption of higher SG&A expenses while maintaining a gross margin of 42.8%. 【Cash Quality】Annualized days sales outstanding were 109 days, inventory turnover days were 266 days, and the cash conversion cycle reached 363 days. Working capital remained tied up for an extended period, particularly as work-in-process inventory accounted for 61.4% of total inventory. 【Investment Efficiency】ROE was 4.1%, decomposed into a net profit margin of 9.7% × total asset turnover of 0.335x × financial leverage of 1.25x, with low total asset turnover acting as a constraint on ROE. 【Financial Soundness】With an equity ratio of 79.7%, a current ratio of 626.8%, and a debt-to-equity ratio of 0.25x, the financial foundation is extremely conservative and financial safety is high.

Cash Flow Analysis

Because cash flow statement figures are not included in the disclosed information, fund movements are assessed based on changes in the balance sheet. Cash and deposits were ¥18.7B, slightly down from ¥19.5B in the same period of the previous year, but accounted for 38.4% of total assets, maintaining a substantial liquidity buffer. Meanwhile, working capital-related assets remained large, including accounts receivable of ¥6.5B, work-in-process inventory of ¥5.6B, and raw materials of ¥3.5B, resulting in an annualized cash conversion cycle of 363 days. Even amid continued profit growth, if these working capital balances continue to increase, growth in cash generation may not keep pace with profit growth. Accordingly, future trends in inventory and accounts receivable balances will be key points of focus in assessing fund movements.

Earnings Quality

The current-period profit growth was primarily supported by improved margins from operating activities. Non-operating income was ¥0.3B, or approximately 2.0% of revenue, and was relatively small, consisting mainly of interest income, foreign exchange gains, and dividend income. A loss on disposal of fixed assets of ¥0.14B recorded in the previous period did not occur in the current period, and this difference was one of the temporary factors boosting the growth rates of ordinary income and net income. The divergence between ordinary income and net income was attributable to the tax burden corresponding to an effective tax rate of 30.4%, with no distortion arising from unusual accounting treatments. However, working capital centered on accounts receivable and work-in-process inventory continues to expand. Since operating cash flow data are not disclosed, careful monitoring is required regarding the speed at which accounting profit growth converts into cash flow.

Earnings Forecast and Guidance

The full-year forecast calls for revenue of ¥26.5B (+6.6% YoY), operating income of ¥3.5B (+4.1% YoY), and ordinary income of ¥3.4B (-3.0% YoY). Progress rates for cumulative Q3 revenue, operating income, ordinary income, and net income were 61.6%, 57.7%, 66.8%, and 59.1%, respectively, below the standard 75% level. Progress in revenue and operating income was particularly low, requiring approximately ¥9.2B in revenue and ¥1.5B in operating income in Q4. Acceleration in Q4 revenue and profit generation will therefore be necessary to achieve the full-year plan.

Shareholder Returns

The Q2 dividend was ¥0, while the full-year dividend forecast is ¥80 per share. Based on forecast full-year EPS of ¥197.34, the forecast payout ratio is approximately 40.5%, below the sustainability benchmark of approximately 60%. As no information regarding share buybacks has been disclosed, the total return ratio has not been calculated. If full-year results progress in line with the plan, there appears to be sufficient capacity to fund dividends; however, because operating cash flow data are not disclosed, dividend coverage on a cash basis cannot be confirmed.

Risk Factors

1. Declining working capital efficiency: Annualized days sales outstanding of 109 days, inventory turnover days of 266 days, and a cash conversion cycle of 363 days are all high. In particular, work-in-process inventory accounts for 61.4% of total inventory, potentially indicating that extended production processes or delays in customer acceptance are slowing cash collection.

2. Variability in segment performance: Revenue in the healthcare equipment business declined by -37.2% YoY, and segment profit turned from a profit of ¥0.32B to a loss of ¥0.07B. Profit is highly dependent on the X-ray residual stress measurement equipment business, which accounts for approximately 61% of total segment profit.

3. Delayed progress toward the full-year plan: Cumulative Q3 progress rates for revenue and operating income were 61.6% and 57.7%, respectively, below the standard 75% level. Accelerated revenue and profit generation will be required in Q4.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Return

Both the operating margin and net profit margin exceed the industry median, placing the company’s profitability in the upper tier of the industry.

Growth and Capital Efficiency

The revenue growth rate is below the industry median, indicating that top-line growth is relatively moderate within the industry.

※Source: Compiled by the Company

Key Takeaways from the Financial Results

1. Improvement in the operating margin to 12.3% (+approximately 2.9pt YoY) and growth in the X-ray residual stress measurement equipment business were the primary features of the current-period results. Profit growth exceeding revenue growth suggests the potential for an improved product mix or fixed-cost absorption.

2. While the financial foundation is extremely conservative, with an equity ratio of 79.7% and a current ratio of 626.8%, ROE remained at 4.1%, with low total asset turnover of 0.335x constraining capital efficiency.

3. The cash conversion cycle reached 363 days due to increases in work-in-process inventory and accounts receivable balances. It will be necessary to monitor future inventory and collection trends to determine whether improved profitability converts into cash flow.

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not constitute a recommendation to invest in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, and you should consult a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was strong at the earnings level despite only modest top-line growth, led by a sharp improvement in gross margin and the X-ray residual-stress measurement equipment business. Revenue rose 1.7% year on year to ¥1.632bn. Operating income increased 33.0% to ¥201m, materially outpacing sales growth. Ordinary income rose 29.9% to ¥229m. Net income increased 45.3% to ¥159m, with EPS rising to ¥116.62 from ¥80.24. Gross margin expanded by 573bp year on year to 42.8%, reflecting cost of sales declining 7.6% while revenue increased. Operating margin expanded by 290bp to 12.3%, placing profitability within the stated good range. Net margin expanded by 294bp to 9.8%, approaching the 10% excellent threshold. The X-ray residual-stress measurement equipment segment was the principal earnings driver, with revenue up 45.8% and segment profit up 66.4%. In contrast, healthcare equipment revenue declined 37.2% and the segment recorded a ¥7m loss. Optical application and special-equipment revenue was broadly stable, but its segment profit declined 9.5%, indicating some mix or cost pressure. SG&A expenses increased 12.1%, substantially faster than revenue, although gross-margin gains more than absorbed this increase in the reported period. Non-operating income of ¥32m, including ¥10m of FX gains and ¥8m of interest income, provided a modest supplement to operating earnings rather than driving the earnings improvement. The prior-year extraordinary loss related to fixed-asset disposal did not recur, contributing to net-income growth exceeding ordinary-income growth. Balance-sheet liquidity is exceptionally strong, with cash and deposits of ¥1.874bn and a 626.8% current ratio. However, the operating cash cycle is elongated, with annualized DSO of 109 days, annualized DIO of 266 days, and an annualized cash conversion cycle of 363 days. Work in process increased 36.7% year on year and constitutes 61.4% of inventory, making production throughput, project completion, and inventory realization central variables for the Q4 outcome. Against full-year guidance, Q3 cumulative progress is 61.6% for revenue, 57.7% for operating income, and 59.1% for net income, below the standard 75% Q3 run rate. The company therefore requires a seasonally stronger Q4, particularly in the X-ray and optical businesses, to achieve its full-year targets.

Profitability Analysis

The reported annualized ROE is 5.5%, decomposed into a 9.7% net profit margin, 0.446x annualized asset turnover, and 1.25x financial leverage. The principal positive DuPont component is margin: net margin improved from approximately 6.8% in the prior-year Q3 to 9.7%, while leverage remains conservative and is not a material source of return enhancement. Annualized asset turnover remains modest for a manufacturing company, reflecting the substantial cash position and inventory held on the balance sheet. Gross margin improved to 42.8% from approximately 37.1%, a 573bp expansion that was the largest driver of the operating-profit increase. Operating margin rose to 12.3% from approximately 9.4%, a 290bp improvement. This margin expansion occurred despite SG&A increasing to ¥497m from ¥443m, or 12.1% year on year, versus just 1.7% revenue growth. The resulting operating leverage is favorable in the current period, but sustained margin expansion will require sales growth and production execution to absorb the elevated fixed cost base. The X-ray residual-stress measurement equipment business is the core business by current segment-profit contribution, generating ¥264m of segment profit on ¥665m of revenue, for a 39.7% segment margin. Its revenue increased 45.8% and segment profit increased 66.4%, with margin improving from 34.8% a year earlier. Optical application and special-equipment revenue rose 1.6% to ¥642m, but segment profit fell 9.5% to ¥174m and margin declined from 30.4% to 27.1%. Healthcare equipment revenue fell to ¥325m from ¥517m and shifted from a ¥32m segment profit to a ¥7m loss, producing a negative 2.3% margin. The segment mix therefore improved consolidated earnings because high-margin X-ray growth more than offset the healthcare contraction. The five-factor analysis also shows a 0.693 tax burden and a 1.141 interest burden; the latter reflects net non-operating financial income and negligible interest expense, rather than debt-funded earnings.

Growth Assessment

Revenue growth of 1.7% was modest, but the composition changed significantly across businesses. X-ray residual-stress measurement equipment added ¥209m of revenue year on year, offsetting a ¥192m decline in healthcare equipment revenue. Optical application and special-equipment revenue increased by ¥10m, providing stability but not a material growth contribution. Revenue recognized at a point in time increased 4.8% to ¥1.465bn, while revenue recognized over time declined 19.4% to ¥168m. The reduction in over-time service revenue is relevant because it may increase reliance on equipment shipment timing and project acceptance in the final quarter. Gross profit increased 17.4% to ¥699m, evidencing materially improved revenue quality at the gross-profit level. The FY2026 plan calls for revenue of ¥2.650bn, operating income of ¥350m, ordinary income of ¥343m, and net income of ¥270m. Q3 cumulative progress is 61.6% for revenue, 57.7% for operating income, 66.8% for ordinary income, and 59.1% for net income, versus a standard 75% at Q3. Revenue progress is 13.4 percentage points below the standard run rate, while operating-income progress is 17.3 points below it. Achieving guidance requires Q4 revenue of approximately ¥1.018bn and operating income of approximately ¥149m, equivalent to a required Q4 operating margin of about 14.6%. This is above the Q3 cumulative 12.3% margin, making delivery dependent on a favorable project and segment mix. The full-year plan implies 6.6% revenue growth and 4.1% operating-income growth, which appears achievable only with a marked Q4 recovery in shipment and project conversion.

Financial Health

Financial health is robust from a liquidity and balance-sheet capitalization perspective. Current assets of ¥3.448bn exceed current liabilities of ¥550m by ¥2.898bn, resulting in a 626.8% current ratio and an identical quick ratio. Cash and deposits of ¥1.874bn alone are more than 3.4 times current liabilities. Total equity is ¥3.885bn, equal to 79.7% of total assets, while total liabilities are only ¥990m. The 0.25x debt-to-equity ratio is conservative and far below the 2.0x level associated with aggressive leverage. There is no apparent short-term debt-driven maturity mismatch: current assets substantially exceed current liabilities and cash provides an ample liquidity buffer. Interest expense was only ¥16 thousand, and interest coverage of 12,562.5x confirms that financing costs do not constrain earnings capacity. The principal non-current obligation is the ¥439m net defined-benefit liability, representing 44.4% of total liabilities and requiring continued monitoring of actuarial assumptions and funding requirements. Trade payables were ¥42m, while electronically recorded operating obligations were ¥171m, showing that supplier obligations are predominantly managed through electronic payables. Accounts receivable declined 24.0% year on year to ¥653m, which improved the reported balance-sheet level but does not eliminate the elevated annualized DSO of 109 days. Work in process increased ¥150m year on year to ¥557m, increasing operating-capital exposure. Intangible assets declined ¥5m, or 29.7%, to ¥1m; the absolute balance is immaterial to asset quality, capital structure, and impairment risk.

Notable B/S Changes

Accounts receivable: -¥206m (-24.0%) to ¥653m - reported receivables fell, although annualized DSO remains elevated at 109 days and collection efficiency remains a key monitoring item. Work in process: +¥150m (+36.7%) to ¥557m - the increase drove WIP to 61.4% of inventory, indicating heightened project-completion, inventory-realization, and cash-conversion risk. Electronically recorded operating obligations: +¥75m (+78.3%) to ¥171m - supplier obligations shifted toward electronic payables, partly supporting the working-capital cycle. Provision for bonuses: -¥67m (-48.5%) to ¥71m - lower accrued bonus obligations reduced current liabilities and contributed to stronger reported liquidity. Other current liabilities: -¥170m (-39.6%) to ¥259m - the reduction contributed to the decline in current liabilities and the exceptionally high current ratio. Intangible assets: -¥5m (-29.7%) to ¥1m - the movement is immaterial in absolute size and does not create a meaningful intangible-asset or impairment exposure.

Cash Flow Quality

Working-capital quality is the principal cash-conversion concern. Annualized DSO is 109 days, substantially above the 60-day warning threshold, indicating slow conversion of recorded sales into cash receipts. Annualized DIO is 266 days, far above the 90-day warning threshold and consistent with a long production and project-delivery cycle. The annualized cash conversion cycle is 363 days, well above the 120-day warning threshold, meaning a significant amount of capital is committed for an extended period before being recovered in cash. The root cause is concentrated in inventories, particularly work in process of ¥557m. Work in process accounts for 61.4% of total inventory, above the 40% warning threshold, which suggests that project completion, acceptance timing, or manufacturing throughput is the key operational bottleneck. Raw materials were ¥350m and declined 4.6% year on year, whereas work in process rose 36.7%; this pattern indicates that the inventory issue is concentrated in conversion through production rather than raw-material accumulation. The increase in WIP is particularly important given the high-margin equipment-oriented business model, where timing of completion can materially affect quarterly revenue, receivables, and cash realization. The ¥171m electronic-payables balance partly supports supplier financing, but does not offset the extended inventory and receivables cycle. Cash and deposits declined ¥78m year on year to ¥1.874bn, although the company retains a substantial liquidity buffer. The investment case should therefore focus on whether WIP converts into completed deliveries, receivables, and cash during Q4 rather than solely on reported profit growth.

Dividend Sustainability

The full-year dividend forecast is ¥80 per share. Based on forecast EPS of ¥197.34, the implied dividend payout ratio is approximately 40.5%. This is below the 60% sustainability benchmark and leaves a meaningful portion of forecast earnings available for retained capital. The implied aggregate dividend commitment is approximately ¥109m based on 1.368 million average shares, versus forecast net income of ¥270m. Retained earnings of ¥1.582bn and cash and deposits of ¥1.874bn provide substantial balance-sheet capacity to support the planned distribution. The interim Q2 DPS was ¥0, indicating that the planned shareholder distribution is concentrated in the year-end dividend. Dividend sustainability is therefore primarily tied to achievement of the ¥270m full-year net-income target and successful working-capital conversion in Q4. The planned ¥80 DPS remains covered by forecast earnings even though cumulative Q3 net-income progress is below the typical seasonal run rate.

Risk Assessment

Business risks include Production and project-completion risk is elevated: work in process is ¥557m, up 36.7% year on year, and represents 61.4% of total inventory. This exceeds the 40% manufacturing warning threshold and raises the risk of delayed acceptance, deferred revenue recognition, cost overruns, or inventory obsolescence., Collection-cycle risk is high, with annualized DSO of 109 days versus the 60-day warning threshold. Slow customer collection can defer cash realization and increase exposure to customer acceptance or credit issues., Healthcare equipment is a material drag on diversification: revenue declined 37.2% year on year and the segment shifted to a ¥7m loss from a ¥32m profit. A sustained recovery is needed to reduce earnings concentration in the X-ray business., X-ray residual-stress measurement equipment is now the dominant segment-profit contributor. Its strong 39.7% segment margin supports earnings, but also increases sensitivity to order timing, customer capital-expenditure cycles, and concentration in specialized industrial demand., The annualized 363-day cash conversion cycle is materially above the 120-day warning level. This is atypically long for efficient manufacturing operations and increases sensitivity to supply-chain disruption, manufacturing delays, and changes in customer delivery schedules., FX gains of ¥10m equaled roughly 4.9% of operating income. Currency movements are not the core earnings driver in Q3, but can create volatility in reported ordinary income..

Financial risks include The ¥439m net defined-benefit liability represents 44.4% of total liabilities. Changes in discount rates, asset returns, or actuarial assumptions could affect other comprehensive income, equity, and future funding needs., The company must generate approximately ¥1.018bn of Q4 revenue and ¥149m of Q4 operating income to meet full-year guidance. This required Q4 operating margin of about 14.6% is above the Q3 cumulative margin of 12.3%., Cash declined ¥78m year on year while the operating cycle remained extended. The current cash position is strong, but a persistent build in WIP or delayed collections could absorb liquidity over time..

Key concerns include High receivable days: the 109-day annualized DSO is a quality alert because it is 49 days above the stated warning threshold. This may reflect project-based billing and acceptance structures, but it heightens cash-conversion risk and warrants monitoring of subsequent collections., High inventory days: annualized DIO of 266 days is 176 days above the warning threshold. The issue is amplified by WIP growth, which makes inventory valuation and delivery execution more consequential., Long cash conversion cycle: the 363-day annualized CCC signals that accounting earnings may take an extended period to convert into operating cash. Its impact is moderated by the company’s net-cash balance sheet, but it remains a constraint on capital efficiency., High WIP ratio: WIP at 61.4% of inventory points to a production-stage concentration rather than raw-material stocking. This can be normal for customized, high-specification equipment, but the year-on-year increase indicates execution risk until completion and customer acceptance occur., SG&A increased 12.1% year on year against 1.7% revenue growth. Current gross-margin improvement absorbed the increase, but weaker volume or an unfavorable segment mix could pressure operating leverage..

Investment Implications

Key takeaways include Q3 earnings growth was margin-led: operating income rose 33.0% and net income rose 45.3% on only 1.7% revenue growth., The X-ray residual-stress measurement equipment business is the core profit engine, generating ¥264m of segment profit and a 39.7% segment margin., Healthcare equipment deterioration is material, with revenue down 37.2% and a shift into a segment loss., The balance sheet is highly resilient, supported by ¥1.874bn of cash, 79.7% equity/assets, a 626.8% current ratio, and 0.25x debt-to-equity., Working-capital intensity is the central counterweight to reported profitability, with 109-day annualized DSO, 266-day annualized DIO, and a 363-day annualized CCC., Full-year guidance requires a strong Q4, especially as operating-income progress of 57.7% is materially below the standard 75% Q3 progress rate..

Metrics to watch include Q4 X-ray residual-stress measurement equipment shipment, acceptance, revenue, and segment-margin trajectory, Healthcare equipment order recovery and return to segment profitability, Work-in-process balance and WIP share of inventory, Annualized DSO, annualized DIO, annualized cash conversion cycle, and subsequent receivable collections, Q4 operating margin relative to the approximately 14.6% required to achieve full-year operating-income guidance, Year-end dividend execution relative to the ¥80 per-share forecast.

Regarding relative positioning, The company combines above-average gross profitability and a very conservative balance sheet with below-benchmark annualized ROE of 5.5% and unusually working-capital-intensive operations. Relative positioning is therefore defined by strong niche-equipment margins and liquidity, offset by segment concentration, healthcare weakness, and a long cash-conversion cycle.